Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT01490086 is registered in ClinicalTrials.gov with Reviva Pharmaceuticals as lead sponsor.

NCT NCT01490086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01490086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Lead sponsor
Reviva Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
March 31, 2013
Enrollment
234 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

acute schizophrenia, schizoaffective disorder